Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Phase 2 Terminated 92 enrolled Prisma Health-Upstate AstraZeneca · collab MedImmune LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an investigator initiated single institution, open-label study to evaluate the antitumor activity, safety, and tolerability of durvalumab in combination with tremelimumab in subjects with select advanced rare solid tumors.

Timeline

Start: 2016-12-01
Primary completion: 2025-09-17
Completion: 2025-09-17

Outcome

Outcome not reported

Stopped (Enrollment): “poor enrollment likely due to expanded availability of immunotherapy for patients”

Publications

Results Edenfield WJ, Chung K, O'Rourke M, Cull E, Martin J, Bowers H, Smith W, Gluck WL. A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers. Oncologist. 2021 Sep;26(9):e1499-e1507. doi: 10.1002/onco.13798. Epub 2021 May 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Durvalumab	Monoclonal antibody	20 mg/kg	Intravenous
Subject	Durvalumab	Monoclonal antibody	1500 mg	Intravenous
Subject	Tremelimumab	Monoclonal antibody	1 mg/kg	Intravenous
Subject	Tremelimumab	Monoclonal antibody	75 mg	Intravenous
Subject	Tremelimumab	Monoclonal antibody	300 mg	Intravenous